TrialHead & neck2020

Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141).

Chia-Jui Yen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.